Patents Examined by Craig D Ricci
  • Absorption promoter and use for same
    Patent number: 11219688
    Abstract: To provide an absorption promotor that is capable of improving the efficiency in absorption of a pharmaceutical drug and that is highly stable, an absorption promotor includes an oxa acid having a structure represented by the formula (1) below, where R1 represents a linear or branched hydrocarbon group having 1 to 40 carbon atoms, one or more but not all carbon atoms of which hydrocarbon group have optionally been substituted by an oxygen atom, a nitrogen atom, or a sulfur atom, the hydrocarbon group being saturated or unsaturated; m represents a real number of 0 to 50; n represents an integer of 1 to 5; and —C(?O)—X represents a functional group capable of chemical reaction.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: January 11, 2022
    Assignee: MORESCO CORPORATION
    Inventors: Mitsuru Sugawara, Yuki Sato, Yoh Takekuma, Shingo Maruyama
  • Method of treatment of Shwachman-diamond syndrome
    Patent number: 11207300
    Abstract: The invention relates to compounds for the treatment of ribosomopathies. In particular, it refers to compounds for the treatment of Shwachman-Diamond Syndrome (SDS) and other ribosomopathies, such as Diamond-Blackfan Anemia (DBA), X-linked dyskeratosiscongenita (DKC) and Treacher Collins syndrome (TCS).
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: December 28, 2021
    Inventor: Marco Cipolli
  • Preservative containing compositions
    Patent number: 11202832
    Abstract: The present invention relates to compositions providing improved preservative efficacy. The present invention further relates to polyquaternium compound containing compositions having improved the antifungal activity. In certain embodiments, the present invention relates to ophthalmic compositions comprising a polyquaternium compound, a polyol or combination of polyols, borate compound, and an antimicrobial mixture comprising electrolytes and nutrients.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: December 21, 2021
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Mingqi Bai, Kenneth T. Holeva
  • Methods for diagnosing and treating eosinophilic esophagitis
    Patent number: 11199543
    Abstract: Disclosed are methods of diagnosing and treating a subject with active or inactive eosinophilic esophagitis (EoE). The methods may include the steps of detecting whether a level of eosinophil lineage-committed progenitor (EoP) is elevated in a blood sample obtained from a subject, diagnosing the subject with active EoE when an EoP level in the sample is elevated above a pre-determined cut-off value and diagnosing the subject with inactive EoE when the EoP level in the sample is below a pre-determined cut-off value; and treating the subject diagnosed with active EoE. Kits related to same are also disclosed.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: December 14, 2021
    Assignee: Children's Hospital Medical Center
    Inventor: Patricia C. Fulkerson
  • Method of controlling anthracnose on tropical fruit plants
    Patent number: 11197478
    Abstract: A method of controlling anthracnose caused by Colletotrichum on tropical fruits, tropical fruit plants or cultivars or plant parts or locus thereof is described. The method comprises the steps of contacting the tropical fruit plant or cultivar in need of treatment with an agrochemical composition comprising an effective amount of a guanidine or a salt and/or solvate thereof. The contacting step may be repeated one or more times at a fixed interval. The guanidine may be dodine, iminoctadine trialbesilate, iminoctadine triacetate, guazatine, salts and/or solvates of any of the foregoing and combinations of one or more of the foregoing.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: December 14, 2021
    Assignee: ARYSTA LIFESCIENCE INC.
    Inventors: Lara Ramaekers, Maurilio Flores Lopez
  • Ionic liquid based support for manufacture of peptides
    Patent number: 11192917
    Abstract: The present invention relates to an ionic liquid based support of Formula-I: wherein: X+ is a heteroatom containing cationic part; W is a halogen containing polymeric solid support; n is an integer in the range of 2 to 8; Y is a hydrophobic anion; R is selected from CO—Z or Z; Z is selected from the group consisting of —Cl, —Br, —OH, —O-Alkyl and combinations thereof. The present invention also relates to a process for preparation of said ionic liquid based support used for di, oligo or polypeptide manufacture.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: December 7, 2021
    Assignee: INDIAN INSTITUTE OF TECHNOLOGY DELHI
    Inventors: Sreedevi Upadhyayula, Tanmoy Patra, Subhasis Paul
  • Use of pharmacological chaperones for the treatment of lysosomal storage diseases
    Patent number: 11192874
    Abstract: The present invention relates to the use of galactose analogues of formula (I) with the capacity to stabilize the structure of the #-GalA enzyme, for the treatment of lysosomal storage diseases and, in a preferred embodiment, for the treatment of Fabry disease. In addition, the present invention relates to pharmacological compositions having an effective amount of at least one of the galactose analogues described in the present document for the treatment of lysosomal storage diseases and, in a preferred embodiment, for the treatment of Fabry disease.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: December 7, 2021
    Assignees: FUNDACION BIOMEDICA GALICIA SUR, UNIVERSIDAD DE VIGO
    Inventors: Saida Ortolano, Pedro Besada Pereira, Carmen Teran Moldes
  • Intranasal delivery of dihydroergotamine by precision olfactory device
    Patent number: 11185497
    Abstract: Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (Cmax) of at least 750 pg/ml, (b) with a mean time to Cmax (Tmax) of DHE of less than 45 minutes, and (c) a mean plasma AUC0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: November 30, 2021
    Assignee: Impel Neuropharma, Inc.
    Inventors: John D. Hoekman, Kelsey H. Satterly, Stephen B. Shrewsbury, Scott Youmans, Christopher Fuller
  • Hydrogels with biodegradable crosslinking
    Patent number: 11181803
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: November 23, 2021
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • Formulations of deoxycholic acid and salts thereof
    Patent number: 11179404
    Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: November 23, 2021
    Assignee: Allergan Sales, LLC
    Inventors: Robert Emil Hodge, Jeffrey Douglas Webster
  • Hydrogels with biodegradable crosslinking
    Patent number: 11179470
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: November 23, 2021
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • Ph-sensitive and bioreducible polymer-virus complex for cancer treatment
    Patent number: 11174465
    Abstract: The present invention relates to a pH-sensitive and bioreducible polymer-virus complex which can destroy tumor cells more effectively by increasing the efficiency of virus transduction, to a pH-sensitive and bioreducible polymer, and to a pharmaceutical composition containing the polymer-virus complex.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: November 16, 2021
    Assignee: GENEMEDICINE CO., LTD.
    Inventors: Chae Ok Yun, Dayananda Kasala
  • Parenteral dosage form of amiodarone
    Patent number: 11166911
    Abstract: The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 9, 2021
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Samarth Kumar, Soni Maheshkumar Parasmal, Milan Mohanbhai Vasoya, Prashant Kane, Subhas Balaram Bhowmick, Rajamannar Thennati
  • Method for enhancing folding and transport of misfolded glucocerebrosidase
    Patent number: 11160773
    Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: November 2, 2021
    Assignees: The Hospital for Sick Children, McMaster University
    Inventors: Don J. Mahuran, Michael B. Tropak, Justin D. Buttner, Jan E. Blanchard, Eric D. Brown
  • Compounds that enhance Atoh1 expression
    Patent number: 11160808
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: November 2, 2021
    Assignees: Massachusetts Eye & Ear Infirmary, Brigham & Women's Hospital, Inc.
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Preparation of nano-sized UV absorbers
    Patent number: 11160743
    Abstract: The invention relates to an improved process for the manufacture of nano-sized organic UV absorbers having a mean particle size distribution (Dv50) determined by light scattering of less than 200 nm.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: November 2, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventor: Bernd Schlegel
  • Composition to shorten drying time for hair
    Patent number: 11154483
    Abstract: Methods and compositions are provided that speed drying time for hair at room temperature. An aerosol hair drying aid composition includes a propellant portion and a liquid portion. The liquid portion includes at least one absorbent, at least one dispersing agent, at least one hair conditioning agent, and at least one non-aqueous solvent.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: October 26, 2021
    Assignee: AMERICAN SPRAYTECH, L.L.C.
    Inventors: Rasheedat Ipaye, Aaysha Mustafa, Manav A. Lalwani
  • Nail lacquer composition containing ciclopirox
    Patent number: 11154542
    Abstract: The present invention relates to a nail lacquer composition containing at least one antifungal agent as a pharmacologically active ingredient. The present invention has an excellent penetrating effect of a drug in skin areas where the drug is applied because of needing treatment and, specifically, in fingernails by containing a polymer material which forms a specific film, and a penetration enhance, is convenient for management after locally applying the drug to a treatment site, and has excellent storage stability of the drug.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: October 26, 2021
    Assignee: GENUONE SCIENCES INC.
    Inventors: Nam-hyang Kim, Yong-baik Cho, Sang-young Jeong, Byoung-chan Bae, Jae-seong Lee, Ji-won Lee, Hong-koo Cho
  • Substituted thiophene oligomers and polymers
    Patent number: 11154059
    Abstract: The present disclosure provides an antimicrobial substrate including a substrate and a polythiophene polymer. The polythiophene polymer has a number of repeated monomer units from n is 5-14 or 30 to 120, a number average molecular weight (Mn) from 1,000 to 4,000 or 10,000 to 40,000; and a polydispersity index (PDI) from 1 to 1.3. The present disclosure also provides the polythiophene polymer and uses thereof.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: October 26, 2021
    Inventors: David G. Whitten, Dylan Brown, Jianzhong Yang, Edward Strach, Mohammed Khalil
  • Prevention of atherosclerotic events with direct factor Xa inhibitors
    Patent number: 11154558
    Abstract: The use of direct factor Xa inhibitors, administered in a dose sufficient to reduce the activity of factor Xa to about 25% less than normal or lower, has the effect of preventing the onset of atherosclerosis, and stabilizing atherosclerotic lesions, and preventing the occurrence or recurrence of atherosclerotic events.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: October 26, 2021
    Assignee: Adams Pharmaceuticals LLC
    Inventors: Jonathan Adams, Peter Jeffrey Adams